Etanercept for the treatment of axial spondyloarthritis

Author(s): I-H Song, J Sieper

The introduction of etanercept (ETN; Enbrel®), and other TNF-blockers, has revolutionized the treatment of patients with ankylosing spondylitis. ETN, as with other approved TNF-blockers, shows good efficacy in treating spinal disease, especially if patients are treated early. Furthermore, studies involving ETN demonstrate good long-term efficacy. This review summarizes the data on ETN in the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis, and discusses topics such as its efficacy in treating extra-articular manifestations, dose modifications and immunogenicity of ETN, and switching between ETN and other TNF-blockers, as well as radiographic progression and safety.